

Medical Preferred Drug List

Medicare Part B Step Therapy

The CVS Caremark[®] Medical Preferred Drug List encourages utilization of clinically appropriate and lower net cost products within the following therapeutic drug classes. The CVS Caremark Medical Preferred Drug List applies to the listed products only and any other product may be available under a plan's medical benefit.

The listed preferred products must be used first. An exception process is in place for specific circumstances that may warrant a need for a non-preferred product. For example, this step therapy requirement does not apply to plan's members who are actively receiving treatment (i.e., members with a paid claim within the past 365 days) with non-preferred product on the CVS Caremark Medical Preferred Drug List.

Drug Class	Non-Preferred Product(s)*	Preferred Product(s)
Alpha-1 Antitrypsin Deficiency	Aralast Glassia	Prolastin-C Zemaira
Autoimmune Infused Infliximab	Avsola Renflexis	Inflectra Infliximab Remicade
Autoimmune Infused/Other	Actemra Cimzia Ilumya Orencia Stelara	Entyvio Simponi Aria

*Non-preferred product(s) are only available if process exception criteria are met.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.



Drug Class	Non-Preferred Product(s)*	Preferred Product(s)
Avastin/Biosimilars (Oncology)	Alymsys Avastin Vegzelma	Mvasi Zirabev
Complement Inhibitors (aHUS, gMG, PNH)		Soliris Ultomiris
Complement Inhibitors (NMOSD)	Uplizna	Soliris
Hematologic, Erythropoiesis – Stimulating Agents (ESA)	Epogen Mircera Retacrit	Aranesp Procrit
Hematologic, Neutropenia Colony Stimulating Factors – Long Acting	Fylnetra Nyvepria Rolvedon Stimufend Udenyca Ziextenzo	Fulphila Neulasta

*Non-preferred product(s) are only available if process exception criteria are met.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.



January 2024

Drug Class	Non-Preferred Product()*	Preferred Product(s)
Hematologic, Neutropenia Colony Stimulating Factors – Short Acting	Granix Leukine Neupogen Nivestym Releuko	Zarxio
Hematopoietic Agents- Iron	Feraheme Injectafer Monoferric	Ferrlecit Infed Sodium Ferric Gluconate Venofer
Hemophilia Factor VIII- Recombinant	Advate Afstyla Kogenate Novoeight Nuwiq Recombinate Xyntha Xyntha Solofuse	Kovaltry
Hemophilia Factor IX- Recombinant		Alprolix Idelvion
Lysosomal Storage Disorders – Gaucher Disease	VPRIV	Cerezyme Elelyso

^{*}Non-preferred product(s) are only available if process exception criteria are met.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.

CVS caremark[®]

January 2024

Drug Class	Non-Preferred Product(s)*	Preferred Product(s)
Multiple Sclerosis (Infused)	Briumvi Lemtrada	Ocrevus Tysabri
Osteoarthritis, Viscosupplements – Multi Injection	Euflexxa Gelsyn-3 GenVisc Hyalgan Hymovis Supartz FX Triluron TriVisc Visco-3	Orthovisc Synvisc
Osteoarthritis, Viscosupplements – Single Injection	Gel-One Monovisc	Durolane Synvisc-One
Prostate Cancer – Luteinizing Hormone Releasing Hormone (LHRH) Antagonists Agents		Firmagon
Rituximab	Riabni Truxima	Rituxan Rituxan Hycela Ruxience
Severe Asthma	Cinqair Nucala Tezspire	Fasenra Xolair

*Non-preferred product(s) are only available if process exception criteria are met.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.



January 2024

Drug Class	Non-Preferred Product(s)*	Preferred Product(s)
Trastuzumab	Herceptin	Kanjinti Trazimera
	Herceptin Hylecta	Irazimera
	Herzuma	
	Ogivri	
	Ontruzant	

*Non-preferred product(s) are only available if process exception criteria are met.

This list indicates the common uses for which the drug is prescribed. Some medicines are prescribed for more than one condition. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. Listed therapeutic classes and specific drug preferred designations are subject to change based on new drug launches, product approvals, drug withdrawals and other market changes.